Clinical effectiveness of exogenous L-arginine in patients with coronary heart disease after community-acquired pneumonia
DOI:
https://doi.org/10.14739/2310-1210.2017.1.91601Keywords:
coronary artery disease, pneumonia, C-reactive protein, neopterin, pregnancy-associated plasma protein-A, pro-brain natriuretic peptide, argininеAbstract
Coronary heart disease and community acquired pneumonia associated with a higher risk for morbidity and mortality. The optimization of treatment of comorbid pathology by medicines which modify endothelium functional state is important.
Aim: to study effect of exogenous L-arginine on clinical course of disease, markers of systemic inflammation and endothelial dysfunction in patients with coronary heart disease (CHD) and community-acquired pneumonia (CAP).
Materials and methods. 60 patients with CHD and CAP (the median 72.50 years, range 66.00; 75.00) were included into the study. Patients were randomized in 2 groups: first – 30 patients with basic therapy combined with L-arginine; and second – 30 patients with basic therapy. hs-CRP, neopterin, РАРР-А, NT-proBNP were measured by ELISA-TEST before treatment and 1 month after. Clinical course was assessed during 1 year of follow-up.
Results. In the first group the hospitalization rate due to CHD and heart failure decompensation was significantly rare. Biomarkers changes in the 1st group were significant: hs-CRP was significantly decreased by 57.14 % (in the 2nd group – by 28.57 %); neopterin – by 36.57 % (in the 2nd group – by 20.91 %); РАРР-А – by 35.71 % (in the 2nd group – by 4.76 %). There was revealed a significant decreasing of NT-proBNP levels in patients receiving L-arginine by comparing with basic therapy: with the I stage of heart failure (HF) – by 50.97 % vs 21.82 %, with the II-A stage of HF – by 43.82 % vs 5.61 % (p < 0.05). After 1 month of therapy patients from the 1st group had significantly lower rates of neopterin – by 16.46 %, and NT-proBNP – by 40.92 % in the subgroup of patients with II-A stage of HF (p < 0.05) compared with patients who received only the basic therapy.
Conclusions. Combination of exogenous L-arginine and basic therapy in patients with CHD and CAP was associated with benign clinical course and positive changes of endothelium functional state, immune and inflammation activation.
References
Kovalenko, V. M., & Kornatskyi, V. M. (2016). Problemy zdorov’ia i medychnoi dopomohy ta model pokrashchannia v suchasnykh umovakh [The problems of health and health care and it's improuvment model in modern conditions]. Kyiv. [in Ukrainian].
Lynnyck, M., Nedospasova, O., Tarasenko, O., Bushura, I., & Nikiforova, L. (2016). Porivnialni dani pro rozpovsiudzhenist khvorob orhaniv dykhannia i medychnu dopomohu khvorym pulmonolohichnoho ta alerholohichnoho profiliu v Ukraini za 2009–2015 rr. [Comparative data on the prevalence of respiratory diseases and medical care for patients with pulmonary and allergy profile diseases in Ukraine for 2009–2015 years]. Kyiv: Lira-K. [in Ukrainian].
Corrales-Medina, V., Suh, K., Rose, G., Chirinos, J., Doucette, S., Cameron, D., & Fergusson, D. (2011). Cardiac Complications in Patients with Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Observational Studies. PLoS Med, 8(6), e1001048. doi: 10.1371/journal.pmed.1001048.
Griffin, A., Wiemken, T., & Arnold, F. (2013). Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. International Journal of Infectious Diseases, 17(12), e1125-e1129. doi: 10.1016/j.ijid.2013.07.005.
Mykhailovska, N. S., Oliinyk, T. V., & Mykhailovskyi, Y. M. (2015). Kliniko-patogenetychna rol imunozapalnykh porushen ta endotelialnoyi dysfunktsii u khvoryh na ishemichnu khvorobu sertsia, komorbidnu z gipotyreozom [Clinical and pathogenetic role of immunoinflammatory disorders and endothelial dysfunction in patients with ischemic heart disease comorbid with hypothyroidism (reference review)]. Bukovynskyi medychnyi visnyk, 19 (1), 227–231. [in Ukrainian].
Lutai, M. I., Bugayenko, V. V., Moiseyenko, O. I., Mushtenko, L. O., & Slobodskyi, V. A. (2011). Znachennia L-arhininu v likuvanni khvorykh iz sertsevo-sudynnoiu patolohiieiu [Value of L-arginine in treatment patients with cardiovascular pathology]. Ukrainskyi kardiolohichnyi zhurnal, 4, 96–107. [in Ukrainian].
Babushkina, A. (2009). L-arginin s tochki zreniya dokazatel´noj mediciny [L-arginine in terms of evidence based medicine]. Ukrainskyi medychnyi chasopys, 6, 43–48. [in Ukrainian].
Bai, Y., Sun, L., Yang, T., Chen, J., & Hui, R. (2008). Kratkovremennyj peroral'nyj priem L-arginina uluchshaet e´ndotelial'nuyu funkciyu natoshhak pri nizkikh iskhodnykh znacheniyakh potokoposredovannoj vazodilatacii: metaanaliz randomizirovannykh kontroliruemykh issledovanij [Short-term oral administration of L-arginine improves endothelial function on the empty stomach at low initial values floro-mediated vasodilation: meta-analysis of randomized controlled trials]. Ukrainskyi medychnyi visnyk. Therapia, 10, 45–51. [in Ukrainian].
Kraidashenko, O. V., & Shalmina, M. A. (2012). E´ndotelijoposredovanyj e´ffekt tivortina u bol´nykh s ishemicheskoj bolezn´yu serdca pozhilogo i starcheskogo vozrasta [Endothelium-derived atiischemic effect of tivortin in elderly patients with ischemic heart disease]. Visnyk problem biolohii i medytsyny, 2, 2(93), 105–109. [in Ukrainian].
Ostrovskyy, M. M., & Varunkiv, O. I. (2013). Vplyv patohenetychno-obhruntovanoi medykamentoznoi terapii nehospitalnoi pnevmonii na tli ishemichnoi khvoroby sertsia v osib, infikovanykh Chlamydophila pneumonia, na endobronkhialni faktory nespetsyfichnoi rezystentnosti ta lokalnu imunnu vidpovid [The influence of pathogenetically substantiated medicinal therapy of community-acquired pneumonia in combination with concomitant coronary artery disease in patients, infected by chlamydophila pneumoniae, on endobronchial nonspecific resistance factors and local immune response]. Ukrainskyi pulmonolohichnyi zhurnal, 3, 63–67. [in Ukrainian].
Treshchinskaya, M. A. (2012). Antie´jdzhingovyj e´ffect L-arginina [Anti-aging effect of L-arginine]. Medicina neotlozhnykh sostoyanij, 3, 50–54. [in Russian].
Shevchenko, A. O., Slesareva, Yu. S., & Shevchenko, O. P. (2011). Laboratornaya diagnostika povrezhdeniya ateroskleroticheskoj blyashki u bol´nykh ishemicheskoj bolezn´yu serdca: PAPP-A (obzor literatury) [Laboratory diagnosis of atherosclerotic plaque damage in patients with coronary heart disease: PAPP-A (a review of literature)] Klinicheskaya laboratornaya diagnostika, 5, 3–10.[in Russian].
Chang, C., Mills, G., Karalus, N., Jennings, L., Laing, R., Murdoch, D., et al. (2013). Biomarkers of Cardiac Dysfunction and Mortality from Community-Acquired Pneumonia in Adults. PLoS ONE, 8(5), e62612. doi: 10.1371/journal.pone.0062612.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
